The quality of life among patients with acne, rosacea, and seborrheic dermatitis is significantly lower when compared with healthy people, and these patients experience more negative feelings about themselves as a result of their skin...
The quality of life among patients with acne, rosacea, and seborrheic dermatitis is significantly lower when compared with healthy people, and these patients experience more negative feelings about themselves as a result of their skin...
On the first day of Spring Dermatology Week 2023, Joseph F. Merola, MD, MMSc, and Joel M. Gelfand, MD MSCE, reviewed the pathogenesis in both joints and skin.
On the first day of Spring Dermatology Week 2023, Joseph F. Merola, MD, MMSc, and Joel M. Gelfand, MD MSCE, reviewed the pathogenesis in both joints and skin.
In this interview, Dr Leitenberger discusses his session, “Mohs for Melanoma Immunohistochemistry (IHC) Refresher,” at the 2023 ACMS Annual Meeting. He covered the topic, “Mohs IHC Interpretation.”
In this interview, Dr Leitenberger discusses his session, “Mohs for Melanoma Immunohistochemistry (IHC) Refresher,” at the 2023 ACMS Annual Meeting. He covered the topic, “Mohs IHC Interpretation.”
Researchers aimed to investigate the association between birth order, sibship size (number of siblings), and the risk of atopic dermatitis and food allergy, which are common manifestations of atopy.
Researchers aimed to investigate the association between birth order, sibship size (number of siblings), and the risk of atopic dermatitis and food allergy, which are common manifestations of atopy.
The US Food and Drug Administration recently announced approval of VYJUVEK (beremagene geperpavec [B-VEC]) for the treatment of wounds in patients ages 6 months and older with dystrophic epidermolysis bullosa.
The US Food and Drug Administration recently announced approval of VYJUVEK (beremagene geperpavec [B-VEC]) for the treatment of wounds in patients ages 6 months and older with dystrophic epidermolysis bullosa.
Explore how patients and providers can align on defining atopic dermatitis (AD) flares to improve communication, treatment decisions, and shared decision-making. Take this interactive quiz to test your knowledge and learn how patient-centered...
Explore how patients and providers can align on defining atopic dermatitis (AD) flares to improve communication, treatment decisions, and shared decision-making. Take this interactive quiz to test your knowledge and learn how patient-centered...
How well do you understand the patient perspective on atopic dermatitis flares? Take this quiz to explore key patient-described flare indicators, emotional and social impacts, and insights from NEA research.
How well do you understand the patient perspective on atopic dermatitis flares? Take this quiz to explore key patient-described flare indicators, emotional and social impacts, and insights from NEA research.
Test your knowledge of how patients with atopic dermatitis (AD) define and experience flares. This quiz highlights key indicators, patient-described attributes, and insights from the NEA’s research into AD flare triggers and symptoms.
Test your knowledge of how patients with atopic dermatitis (AD) define and experience flares. This quiz highlights key indicators, patient-described attributes, and insights from the NEA’s research into AD flare triggers and symptoms.
1. How do JAK inhibitors differ from traditional immunosuppressant treatments for atopic dermatitis?a) They work extracellularly, directly blocking cytokines.b) They target inflammation at the intracellular level and are more selective.c)...
1. How do JAK inhibitors differ from traditional immunosuppressant treatments for atopic dermatitis?a) They work extracellularly, directly blocking cytokines.b) They target inflammation at the intracellular level and are more selective.c)...